RxDoctor Payments Data

Robert Mobley, MD

Ophthalmology · Clinton Township, MINPI 1467435537

Payments from drug & device makers

$2,109in general payments, 2019–2025

Across 54 payments — averaging $39.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$639
  • AbbVie$294
  • Topcon Healthcare, Inc.$252
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$165
  • Regeneron Healthcare Solutions, Inc.$127
  • Aerie Pharmaceuticals, Inc.$114
  • plus $519 from 11 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$1,91691%
  • Education$894%
  • Entertainment$924%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,109 in reported general payments places this provider in the 60th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$494,976
Medicare patients
518
Services billed
4,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost167$60,299
RestasisCyclosporine36$46,273
Cyclosporine46$33,463
Brimonidine Tartrate66$10,662
SimbrinzaBrinzolamide/Brimonidine Tart43$10,256
RhopressaNetarsudil Mesylate19$6,044
Bromfenac Sodium18$4,653
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol33$4,032
Latanoprost263$3,669
Lotemax SmLoteprednol Etabonate14$3,425
Dorzolamide-TimololDorzolamide/Timolol/Pf25$2,923
TafluprostTafluprost/Pf14$2,779
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat97$2,107
Tobramycin-DexamethasoneTobramycin/Dexamethasone58$2,009
Fluorometholone32$1,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$294$106,572203 claims
AlconSimbrinza$639$10,25643 claims
Aerie Pharmaceuticals, Inc.Rhopressa$114$6,04419 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$165$3,42514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Clinton Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →